Institutional, Market and Foreign Exchange Risks in Overseas Operations in China
First written in FY2019. 3 of 6 entries say "Restated". Latest entry: FY2021-Q2.
The whole theme swung hardest in 2022: 3 of 6 companies on the "Worse" side.
2 other companies' latest entry also says "Mitigated".
- FY2021-Q2MitigatedAnnual report
「Because the outlook became extremely uncertain due to the impact of COVID-19, the joint venture agreement was terminated on 31 August 2020.」
The termination of the Chinese joint venture agreement and completion of the related procedures reduced the company's business exposure to the former Chinese joint venture business. - FY2021-Q1RestatedAnnual report
「During the cumulative first quarter, there were no material changes concerning newly arising risks or material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the institutional, market and foreign exchange risks relating to the overseas business in China. - FY2020MaterialisedAnnual report
「An impairment loss on investments in an affiliated company was recorded because the actual value of the investment in the joint venture had declined substantially.」
For the overseas business in China, expected sales were not recognized and the actual value of the investment in the joint venture declined, resulting in an impairment loss of ¥9.603 million. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter, there were no material changes concerning newly arising risks or material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the institutional, market and foreign exchange risks relating to the overseas business in China. - FY2020-Q1RestatedAnnual report
「During the cumulative first quarter, there were no material changes concerning newly arising risks or material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the institutional, market and foreign exchange risks relating to the overseas business in China. - FY2019First statedAnnual report
「In November 2018, our company established Hangzhou Fangbu Health Technology Co., Ltd. in Zhejiang Province, China, as a joint venture with Chinese companies and other parties, and invested 25%. We will conduct sufficient investigations before pursuing future business expansion. However, unexpected changes in Chinese administrative authorities or local market conditions, events such as terrorist activity or infectious diseases, or problems involving transactions, logistics, quality control or taxation could affect the overseas business operations of our group.」
The company has identified the effects of administrative and market conditions, terrorism and infectious diseases, transactions, logistics, quality control and taxation, and foreign exchange fluctuations as new risks relating to the overseas joint venture in China.